In July of 2019, Salarius Pharmaceuticals listed on NASDAQ (SLRX) via a reverse merger with Flex Pharma

This significant milestone was made possible by the strategic vision of senior-level management and Board members, investment bankers, and of course the talented team of scientists and advisors who worked collaboratively advancing the company’s lead compound, Seclidemstat, into Phase 1/2 clinical studies.

The public offering provided Salarius with increased access to capital via equity lines and shelf offerings (S-1 / S-3) resulting in the company raising $40M of capital as a public company.

Salaries Rings The Bell At NASDAQ



Complete List of Transactions

Deal Sheet 2-17

Tombstones 2016-2021